Rentschler Biopharma – Your trusted CDMO partner from concept to market

Rentschler Biopharma is a leading global contract development and manufacturing organization (CDMO) offering process development and cGMP manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies. Rentschler Biopharma is a family-owned company headquartered in Laupheim, Germany, with a second site, Rentschler Biopharma Inc. in Milford, MA, USA. A third site in Stevenage, UK, is dedicated to cell and gene therapies. In 2023, Rentschler Biopharma contributed to four of the seventeen, which equals nearly 25%, new biopharmaceuticals approved by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) (Rentschler Biopharma Contributes to Nearly 25% of FDA Approved Biopharmaceuticals) (Rentschler Biopharma Contributes To Nearly 25% of FDA-Approved Biopharmaceuticals). The company is committed to advancing medicine to save lives and helps provide essential therapies for millions of patients with serious and rare diseases.

In recent years, Rentschler Biopharma Inc. in Milford, MA, has grown from a single-product commercial facility to a multi-product facility. A new state-of-the-art manufacturing facility at the existing site, the Rentschler Biopharma Manufacturing Center (RBMC), adds 22,000 square feet of manufacturing cleanroom space and houses four new 2,000 L single-use bioreactors. This is the largest expansion in the company’s more than 150-year history and will double Rentschler Biopharma’s global cGMP capacity. The facility will primarily focus on the commercial production of highly complex molecules for international clients and will be operational this year. In December 2023, the Company announced that it had secured a major client for the RBMC for an innovative protein therapeutic for a form of cancer (Rentschler Biopharma Announces Major Client Project for New US Facility at Milford). By contributing to the global availability of biopharmaceuticals, Rentschler Biopharma, Milford recently won the Gold MassEcon Impact Award (Rentschler Biopharma Takes Home the Gold MassEcon Impact Award), for its strong commitment to diversity as well as its community presence, including its partnerships with local schools and organizations.